Personalized Melanoma Vaccine Cuts Recurrence and Death Risk by 42% in Trial
Source Summary
An international trial found that intismeran, a personalized therapeutic cancer vaccine made from each patient's own tumor, combined with pembrolizumab immunotherapy after surgery reduced the risk of melanoma recurrence or death by 42% in high-risk patients. This marks the first such trial of a personalized vaccine approach for melanoma.
Why it matters
This result demonstrates a significant clinical benefit for a new personalized vaccine approach in treating high-risk melanoma, potentially offering patients a new treatment option to reduce recurrence and mortality after surgery.
